Treatment strategies in toxic epidermal necrolysis syndrome: Where are we at?

Journal of Burn Care and Research

Volumn 29, Issue 1, 2008, Pages 269-276

  Abood, Gerard J ^a   Nickoloff, Brian J ^a   Gamelli, Richard L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; CONJUNCTIVITIS; DIAGNOSTIC VALUE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKOPENIA; NEUTROPENIA; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PATIENT TRANSPORT; PLASMAPHERESIS; PROGNOSIS; REVIEW; SCORING SYSTEM; SKIN ALLOGRAFT; SKIN GRAFT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

BURN UNITS; BURNS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; NUTRITIONAL SUPPORT; PROGNOSIS;

EID: 38049091509     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31815f3658     Document Type: Review

References (105)

1. Arnold HJ, Odom RB, James WD. Contact dermatitis; drug eruptions. In: Andrew's diseases of the skin: clinical dermatology. Philadelphia, PA: WB Saunders; 1990. p. 128-30.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361.
3. Roujeau J. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-9.
4. Roujeau J, et al. Toxic epidermal necrolysis (Lyell Syndrome): incidence and drug-etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
5. Guillaume JC, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987;123:1166-70.
6. Hawk RJ, Storer JS, Daum RS. Toxic epidermal necrolysis in a 6-week-old infant. Pediatr Dermatol 1985;2:197-200.
7. Roujeau JC, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
8. Fritsch P, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-60.
9. Dreyfuss DA, et al. Survival after a second episode of toxic epidermal necrolysis. Ann Plast Surg 1988;20:146-7.
10. Pegram PS Jr, Mountz JD, O'Bar PR. Ethambutol-induced toxic epidermal necrolysis. Arch Intern Med 1981;141:1677-8.
11. Schmidt D, Kluge W. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. Epilepsia 1983;24:440-3.
12. Kaufmann D. Epidemiologic approaches to the study of toxic epidermal necrolysis. J Invest Dermatol 1991;102:31S-33S.
13. Schopf E, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
14. Shear NH, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-84.
15. Wolkenstein P, et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131:544-51.
16. Reilly T, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164-73.
17. Wolkenstein P, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995;5:255-8.
18. Wolkenstein P, et al. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 1998;113:39-50.
19. Rzany B, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:1059.
20. Dolan P, et al. Toxic epidermal necrolysis. J Emerg Med 1989;7:65-69.
21. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2 and 3: a study of sixty cases. J Am Acad Dermatol 1985;13:623-635.
22. Becker D. Toxic epidermal necrolysis. Lancet 1998;351:1417-1419.
23. Oplatek A, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26-33.
24. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997;19:127-32.
25. Paul C, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-14.
26. Viard I, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
27. Posades S, et al. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reaction to drugs. Blood Cells Mol Dis 2002;29:179-89.
28. Paquet P, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-8.
29. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
30. Garcia-Doval I, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
31. Demling RH, Ellerbe S, Lowe NJ. Burn unit management of toxic epidermal necrolysis. Arch Surg 1978;113:758-9.
32. Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995;180: 340-2.
33. Kelemen JJ III, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8.
34. Macfarlane AW, Curley RK. Management of toxic epidermal necrolysis with a hydrogel dressing and fluidized-bead bed: report of three cases. Clin Exp Dermatol 1987;12:354-6.
35. Heimbach DM, et al. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987;257:2171-5.
36. Birchall N, et al. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 1987;16(2, Pt 1):368-72.
37. Pruitt BA Jr. Burn treatment for the unburned. JAMA 1987;257:2207-8.
38. Prasad JK, Feller I, Thomson PD. Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma 1986;26:945-6.
39. Bradley T, et al. Toxic epidermal necrolysis: a review and report of the successful use of biobrane for early wound coverage. Ann Plast Surg 1995;35:124-32.
40. Roujeau JC, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23(6, Pt 1):1039-58.
41. Asz J, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006;41:e9-e12.
42. Clennett S, Hosking G. Management of toxic epidermal necrolysis in a 15-year-old girl. J Wound Care 2003;12:151-4.
43. Power WJ, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/ toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669-76.
44. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol 1973;90:376-9.
45. Foster CS, et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988;95:453-62.
46. Bastuji-Garin S, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
47. Palmieri TL, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96.
48. Imahara SD, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006;27:270-5.
49. Wolkenstein P, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
50. Barnichas G, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002;6:225-8.
51. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-6.
52. Chaidemenos GC, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36:218-21.
53. Egan CA, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-61.
54. Gerard A, et al. Lyell's syndrome treated by plasma exchange. Plasm Ther Transfus Technol 1984;5:259-60.
55. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
56. Sakellariou G, et al. Plasma exchange (PE) treatment in druginduced toxic epidermal necrolysis (TEN). INT J Artif Organs 1991;14: 634-638.
57. Uchino S, et al. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002;28:651-5.
58. Furubacke A, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999;25:1307-10.
59. Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.
60. Arevalo JM, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8.
61. Jarrett P, Ha T, Snow J. Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 1997;22:254.
62. Jarrett P, et al. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997;22:146-7.
63. Murdoch S, Fenton D. Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 1997;22:250-256.
64. Paquet P, et al. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005;297:266-73.
65. Renfro L, Grant-Kels JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989;28:441-4.
66. Robak E, et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med 2001;32:31-9.
67. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996;37:208-12.
68. Szepietowki J, et al. Toxic epidermal necrolysis successfully treated with cyclosporin. Report of three cases. J Eur Acad Dermatol Venereol 1997;9:169-72.
69. Frangogiannis NG, et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996;89:1001-3.
70. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1991;25(5, Pt 1):778-86.
71. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002;28:69-78.
72. Trautmann A, et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-46.
73. Anhalt G, Snelling CF. Toxic epidermal necrolysis. Case report. Plast Reconstr Surg 1978;61:905-10.
74. Bjornberg A. Fifteen cases of toxic epidermal necrolysis (Lyell). Acta Derm Venereol 1973;53:149-52.
75. Finlay AY, Richards J, Holt PJ. Intensive therapy unit management of toxic epidermal necrolysis: practical aspects. Clin Exp Dermatol 1982;7:55-60.
76. Simons HM. Acute life-threatening dermatologic disorders. Med Clin North Am 1981;65:227-43.
77. Ducic I, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768-73.
78. Rasmussen JE. Toxic epidermal necrolysis. A review of 75 cases in children. Arch Dermatol 1975;111:1135-9.
79. Schulz JT, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
80. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil 1997;18:417-20.
81. Guibal F, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-72.
82. Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991;71:171-2.
83. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-4.
84. Jones WG, et al. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg 1989;24:167-70.
85. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-8.
86. Prendiville JS, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-7.
87. Sheridan RL, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20:497-500.
88. Ward DJ, Krzeminska EC, Tanner NS. Treatment of toxic epidermal necrolysis and a review of six cases. Burns 1990;16:97-104.
89. Haslett PA, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-92.
90. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-4.
91. Strieter RM, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-6.
92. Reed WR, DeGowin RL. Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 1992;119:763-71.
93. Redondo P, et al. Toxic epidermal necrolysis. Treatment with pentoxifylline. Br J Dermatol 1994;130:688-9.
94. Sanclemente G, et al. Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 1999;38:878-9.
95. Fischer M, et al. Antitumor necrosis factor-alpha antibodies(infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:707-9.
96. Hunger RE, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005;116:923-4.
97. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996;135:305-6.
98. Winfred RI, et al. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. South Med J 1999;92:918-20.
99. Prins C, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
100. Stella M, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203:45-9.
101. Trent JT, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003;139:39-43.
102. Tristani-Firouzi P, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47:548-52.
103. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
104. Brown KM, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8.
105. Shortt R, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.